Alginate inserts loaded with epidermal growth factor for the treatment of keratoconjunctivitis sicca

Christoph Koelwel; Stefan Rothschenk; Barbara Fuchs-Koelwel; Bernhard Gabler; Chris Lohmann; Achim Göpferich

doi:10.1080/10837450801949566

Alginate inserts loaded with epidermal growth factor for the treatment of keratoconjunctivitis sicca

Christoph Koelwel, Stefan Rothschenk, Barbara Fuchs-Koelwel, Bernhard Gabler, Chris Lohmann, Achim Göpferich

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

We developed and tested ocular inserts containing epidermal growth factor (EGF) for a causal treatment of keratoconjunctivitis sicca (KCS). The inserts, consisting of different alginates with hydroxyethylcellulose (HEC) as a lubricant and release modifier, released EGF over time periods ranging from a few hours up to several days. The stability of EGF was high, having a protein half-life of approximately 548 days. A clinical pilot study suggests an amelioration of both the main symptoms and the objective criteria: tear film break-up (BUT) time and lissamine green score. Our results show that EGF treatment of KCS is highly promising.

Original language	English
Pages (from-to)	221-231
Number of pages	11
Journal	Pharmaceutical Development and Technology
Volume	13
Issue number	3
DOIs	https://doi.org/10.1080/10837450801949566
State	Published - May 2008
Externally published	Yes

Keywords

Alginates
Dry eye
EGF
Ocular insert

Access to Document

10.1080/10837450801949566

Cite this

@article{588619a2572a45cc90a6142e3788f131,

title = "Alginate inserts loaded with epidermal growth factor for the treatment of keratoconjunctivitis sicca",

abstract = "We developed and tested ocular inserts containing epidermal growth factor (EGF) for a causal treatment of keratoconjunctivitis sicca (KCS). The inserts, consisting of different alginates with hydroxyethylcellulose (HEC) as a lubricant and release modifier, released EGF over time periods ranging from a few hours up to several days. The stability of EGF was high, having a protein half-life of approximately 548 days. A clinical pilot study suggests an amelioration of both the main symptoms and the objective criteria: tear film break-up (BUT) time and lissamine green score. Our results show that EGF treatment of KCS is highly promising.",

keywords = "Alginates, Dry eye, EGF, Ocular insert",

author = "Christoph Koelwel and Stefan Rothschenk and Barbara Fuchs-Koelwel and Bernhard Gabler and Chris Lohmann and Achim G{\"o}pferich",

year = "2008",

month = may,

doi = "10.1080/10837450801949566",

language = "English",

volume = "13",

pages = "221--231",

journal = "Pharmaceutical Development and Technology",

issn = "1083-7450",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Alginate inserts loaded with epidermal growth factor for the treatment of keratoconjunctivitis sicca

AU - Koelwel, Christoph

AU - Rothschenk, Stefan

AU - Fuchs-Koelwel, Barbara

AU - Gabler, Bernhard

AU - Lohmann, Chris

AU - Göpferich, Achim

PY - 2008/5

Y1 - 2008/5

N2 - We developed and tested ocular inserts containing epidermal growth factor (EGF) for a causal treatment of keratoconjunctivitis sicca (KCS). The inserts, consisting of different alginates with hydroxyethylcellulose (HEC) as a lubricant and release modifier, released EGF over time periods ranging from a few hours up to several days. The stability of EGF was high, having a protein half-life of approximately 548 days. A clinical pilot study suggests an amelioration of both the main symptoms and the objective criteria: tear film break-up (BUT) time and lissamine green score. Our results show that EGF treatment of KCS is highly promising.

AB - We developed and tested ocular inserts containing epidermal growth factor (EGF) for a causal treatment of keratoconjunctivitis sicca (KCS). The inserts, consisting of different alginates with hydroxyethylcellulose (HEC) as a lubricant and release modifier, released EGF over time periods ranging from a few hours up to several days. The stability of EGF was high, having a protein half-life of approximately 548 days. A clinical pilot study suggests an amelioration of both the main symptoms and the objective criteria: tear film break-up (BUT) time and lissamine green score. Our results show that EGF treatment of KCS is highly promising.

KW - Alginates

KW - Dry eye

KW - EGF

KW - Ocular insert

UR - http://www.scopus.com/inward/record.url?scp=45849121753&partnerID=8YFLogxK

U2 - 10.1080/10837450801949566

DO - 10.1080/10837450801949566

M3 - Article

C2 - 18484491

AN - SCOPUS:45849121753

SN - 1083-7450

VL - 13

SP - 221

EP - 231

JO - Pharmaceutical Development and Technology

JF - Pharmaceutical Development and Technology

IS - 3

ER -

Alginate inserts loaded with epidermal growth factor for the treatment of keratoconjunctivitis sicca

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this